This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third look: Understanding the impact, use, and prescribing patterns for XELJANZ (tofacitinib) in Rheumatoid Arthritis.
Ticker(s): PFEWho's the expert?
- Passionate about preventative health care and assisting his patients to achieve both short and long-term optimization of their health and well-being.
- Is a member of the American College of Physicians (ACP) and the American College of Rheumatology (ACR).
- Academic interests include inflammatory myopathies and novel therapeutic targets in spondvloarthropathv research
- Keen interest in chronic arthritic pain and the potential for the development of substance abuse disorders.
- Interest in addiction medicine and harm reduction approaches to combat the growing opioid epidemic in the United States and Canada.
- Recently completed additional training and received certification from the Substance Abuse and Mental Health Services Administration (SAMHSA) and is authorized to prescribe buprenorphine (Suboxone) for those suffering from opioid addiction
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
